Benzinga · Sep 8, 2026
Needham Reiterates Buy on BioCryst Pharma, Maintains $16 Price Target
Needham analyst Serge Belanger reiterates BioCryst Pharma (NASDAQ:BCRX) with a Buy and maintains $16 price target.
NASDAQ · BCRX
BioCryst Pharmaceuticals, Inc.
Healthcare · Biotechnology
$8.29
Down-$0.52 (-5.85%)
Updated Sep 11, 2026, 4:59 AM
SID Score
4.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.6B
- P/E ratio
- -181.47
- Dividend yield
- 0.00%
- 52-week range
- $7.79 – $11.22
- Volume
- 9M
- Avg. volume
- 4.95M
Price performance
BCRX price history
1M range · 20 trading sessions · Daily adjusted prices
BCRX closed at $8.29 after 20 trading sessions, down 15.49% for the selected period.
- Last close
- $8.29
- Period change
- -15.49%
- Period low
- $8.29
- Period high
- $10.17
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $8.34 | $8.46 | $8.045 | $8.29 | 9M |
| Sep 9, 2026 | $9.07 | $9.23 | $8.80 | $8.805 | 5.15M |
| Sep 8, 2026 | $9.122 | $9.40 | $8.96 | $9.065 | 9.69M |
| Sep 4, 2026 | $10.00 | $10.10 | $9.895 | $9.96 | 1.5M |
| Sep 3, 2026 | $10.15 | $10.22 | $9.935 | $10.09 | 1.97M |
| Sep 2, 2026 | $10.00 | $10.23 | $9.83 | $10.17 | 3.13M |
| Sep 1, 2026 | $9.72 | $9.955 | $9.63 | $9.92 | 3.37M |
| Aug 31, 2026 | $9.72 | $9.72 | $9.46 | $9.70 | 2.76M |
| Aug 28, 2026 | $9.822 | $9.96 | $9.72 | $9.82 | 2.7M |
| Aug 27, 2026 | $9.75 | $9.92 | $9.551 | $9.87 | 2.48M |
| Aug 26, 2026 | $9.77 | $9.90 | $9.71 | $9.83 | 1.86M |
| Aug 25, 2026 | $9.79 | $9.9161 | $9.698 | $9.83 | 2.33M |
| Aug 24, 2026 | $9.50 | $9.755 | $9.48 | $9.68 | 2.01M |
| Aug 21, 2026 | $9.72 | $9.905 | $9.48 | $9.55 | 2.5M |
| Aug 20, 2026 | $9.92 | $9.9883 | $9.595 | $9.66 | 2.33M |
| Aug 19, 2026 | $9.93 | $10.11 | $9.765 | $10.07 | 2.91M |
| Aug 18, 2026 | $9.89 | $9.94 | $9.545 | $9.70 | 2.12M |
| Aug 17, 2026 | $9.72 | $10.025 | $9.65 | $9.94 | 2.12M |
| Aug 14, 2026 | $9.68 | $9.7999 | $9.46 | $9.74 | 3.82M |
| Aug 13, 2026 | $10.59 | $10.63 | $9.70 | $9.81 | 4.58M |
Latest BCRX news
The latest Smart Investors Daily articles mentioning BCRX.
Stock researchCompany · Overview
BCRX research
Overview
Company profile and research snapshot.
Company profile
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $14.40
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 10, 2026 | RBC Capital | Sector Perform | — |
| Sep 8, 2026 | Needham | Buy | — |
| Aug 6, 2026 | RBC Capital | Outperform | — |
| Aug 6, 2026 | Wedbush | Outperform | — |
| Jul 13, 2026 | JP Morgan | Neutral | — |
News briefing
Generated Sep 10, 2026, 9:08 PM
Why Is BCRX Down Today?
BioCryst Pharmaceuticals shares declined 5.85% despite receiving continued analyst support, suggesting broader market headwinds or profit-taking may be outweighing positive research coverage. The stock's weakness comes even as Needham maintained its bullish stance on the biotech company, indicating investor sentiment may be driven by factors beyond current analyst recommendations.
Bottom line: BioCryst's 5.85% decline appears disconnected from analyst sentiment, with Needham maintaining its Buy rating and $16 target despite today's weakness. Investors should distinguish between biotech sector headwinds and company-specific concerns, while watching for upcoming clinical or commercial catalysts that could re-ignite investor interest and validate the research community's bullish view.
Yahoo · Sep 2, 2026
Billionaire Portfolios: 2 Under-$20 Healthcare Stock Picks
The recent breakout of Moderna reminded investors that AI stocks aren’t the only destination to make money. Healthcare and biotech stocks offer promising long-term opportunities if chosen wisely. We ran an analysis based on Insider Monkey’s proprietary database of over 900 hedge funds to see which healthcare stocks trading under $20 billionaire-led funds were holding […]
Yahoo · Sep 1, 2026
BioCryst to Present at Upcoming Investor Conference
RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Tuesday, September 15, 2026, at 9:15 a.m. ET. The link to the live audio webcast and replay of the presentation may be accessed in the Investors & Media section of BioCryst’s website at www.biocryst.com. About BioCryst Pharmaceuticals BioCryst is a global biote
Yahoo · Aug 31, 2026
Is BioCryst Pharmaceuticals (BCRX) Stock Outpacing Its Medical Peers This Year?
Here is how BioCryst Pharmaceuticals (BCRX) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
